Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Mayne Pharma Group's
Operating Income
for the
six
months ended in Dec. 2025 was A$-54.4 Mil. Mayne Pharma Group's Interest Expense for the
six
months ended in Dec. 2025 was A$-2.4 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Mayne Pharma Group's Interest Coverage or its related term are showing as below:
ASX:MYX's Interest Coverage is not ranked *
in the Medical Distribution industry.
Industry Median: 6.92 * Ranked among companies with meaningful Interest Coverage only.
Mayne Pharma Group (ASX:MYX) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Mayne Pharma Group Interest Coverage Related Terms
Mayne Pharma Group Interest Coverage Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:MYX vs MCK, COR, CAH: Interest Coverage Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Interest Coverage vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Mayne Pharma Group did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Mayne Pharma Group (ASX:MYX) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #999999 out of 91 companies in the Medical Distribution industry.
Is Mayne Pharma Group's Interest Coverage too high?
Mayne Pharma Group's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Mayne Pharma Group ranks #999999 out of 91 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Interest Coverage compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #999999 out of 91 companies for Interest Coverage. This places Mayne Pharma Group in the lower half of its industry. The industry median Interest Coverage is 6.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Distribution company?
The median Interest Coverage among Medical Distribution companies is 6.92, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Interest Coverage is 6.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
Interest Coverage: 0 (At Loss)
GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score
Get the complete analysis for ASX:MYX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 
